Lin Cai

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

Lin Cai, Jie Gu, Jie Zheng et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 99 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

Lin Cai, Xu Yao, Jun Gu et al. · Chinese Medical Journal · 2020 · 48 citations · Full text

Medicine, Dermatology, Pharmacotherapy +12

Distribution of Serotypes, Genotypes, and Resistance Determinants among Macrolide-Resistant <i>Streptococcus pneumoniae</i> Isolates

Xiaoping Xu, Lin Cai, Meng Xiao et al. · Antimicrobial Agents and Chemotherapy · 2010 · 39 citations · Full text

Life Sciences, Genetics, Microbiology +17

A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis

Lin Cai, Gen-Hui Chen, Qianjin Lu et al. · Chinese Medical Journal · 2020 · 37 citations · Full text

Medicine, Dermatology, Pharmacology +13

Risk factors for survival in patients with von Hippel-Lindau disease

Jiangyi Wang, Shuanghe Peng, Teng Li et al. · Journal of Medical Genetics · 2018 · 29 citations

Life Sciences, Genetics, Oncology +16